Injectable GLP-1 Pathway

GLP-1 injectable therapy refers to treatment with prescription medicines such as Mounjaro (tirzepatide), Ozempic (semaglutide) and Wegovy (semaglutide). These once-weekly injections act on incretin hormone receptors involved in appetite regulation, gastric emptying and glucose metabolism thus helping patients consume fewer calories while supporting medically supervised weight management.

After injection, the medication binds to GLP-1 receptors throughout the body, increasing feelings of fullness, delaying gastric emptying and reducing hunger signals sent to the brain.Tirzepatide (Mounjaro) also activates GIP receptors, providing dual incretin activity that may enhance weight-loss outcomes in appropriate patients.

Although all three belong to the incretin medication class, they differ in their active ingredients and receptor activity. Ozempic and Wegovy both contain semaglutide, while Mounjaro contains tirzepatide, which stimulates both GLP-1 and GIP receptors. At Yoyime, our doctor will recommend the most appropriate injectable based on your health profile, medical history and treatment goals.

Injectable therapy is generally considered for adults who are obese or overweight accompanied by weight-related medical conditions, particularly when lifestyle measures alone have not produced sufficient results. Suitability is determined through a clinical assessment rather than BMI alone.

These medications are generally avoided during pregnancy and breastfeeding and may not be appropriate for individuals with certain endocrine disorders, previous pancreatitis, severe gastrointestinal disease or a personal or family history of medullary thyroid carcinoma or MEN2. Yoyime’s specialist doctors will assess individual risks before prescribing.

Before treatment begins at Yoyime, our doctor confirms your suitability, explains how the medication works, reviews possible adverse effects and contraindications and provides detailed instructions on safe administration, dose escalation and storage.

At Yoyime clinic, the medication is administered once weekly using a pre-filled injection pen. It is injected into the subcutaneous fat of the abdomen, thigh or upper arm, with injection sites rotated regularly to minimise irritation and maintain consistent absorption.

Yes. Most patients self-administer their injections at home after receiving training from their healthcare provider on correct injection technique, pen preparation, needle disposal and safe medication handling.

The injection uses a very fine needle and is generally well tolerated. Most patients experience only brief, mild discomfort or no noticeable pain during administration.

At Yoyime clinic, GLP-1 medications are introduced using a structured dose-escalation schedule. Starting at a lower dose allows the body to adapt while reducing the likelihood of gastrointestinal side effects before progressing to higher maintenance doses.

The most commonly reported effects include nausea, vomiting, constipation, diarrhoea, bloating, indigestion and reduced appetite. These symptoms are usually most noticeable during dose escalation and often improve as treatment continues.

A missed dose can often be administered within a specific timeframe, depending on how many days have passed before your next scheduled injection. Yoyime’s expert doctor or pharmacist will advise you on the safest approach based on the manufacturer's prescribing guidance.

Injection pens should be stored according to the manufacturer's instructions, typically refrigerated before first use. Depending on the product, they may remain at room temperature for a limited period after opening. Avoid freezing the medication or exposing it to excessive heat or direct sunlight.

As GLP-1 therapy slows gastric emptying, it can alter the absorption of some oral medications. Patients taking diabetes medications, insulin, anticoagulants or other long-term medicines must inform the doctor before starting treatment.

Yes. Ongoing medical review at Yoyime clinic helps assess weight-loss response, tolerability, side effects and whether dose adjustments are required. Periodic blood tests may also be recommended depending on your medical history and overall health.

Treatment duration varies between individuals. Some patients use injectable therapy for several months, while others benefit from longer-term treatment. Our doctors will review your progress regularly and determine whether to continue, maintain, taper or discontinue therapy based on your clinical response.

Treatment should not be discontinued without discussing it with Yoyime’s expert doctors. Stopping suddenly may increase appetite and contribute to weight re-gain, so any decision to stop is usually made as part of a personalised treatment plan.

No. Mounjaro, Ozempic and Wegovy are prescription-only medicines regulated by the Dubai Health Authority (DHA) and MOHAP. They must be prescribed by a licensed physician and obtained through a licensed pharmacy as part of ongoing medical care.